Virtu Financial LLC Makes New $46,000 Investment in Exagen Inc. (NASDAQ:XGN)

Virtu Financial LLC acquired a new stake in shares of Exagen Inc. (NASDAQ:XGN) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 11,203 shares of the company’s stock, valued at approximately $46,000.

Separately, Corient Private Wealth LLC purchased a new position in shares of Exagen in the 4th quarter worth about $45,000. 75.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 price objective on shares of Exagen in a research report on Monday, January 13th. William Blair reaffirmed an “outperform” rating on shares of Exagen in a report on Wednesday, March 12th. Finally, Canaccord Genuity Group lifted their price objective on Exagen from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Friday, January 3rd.

Exagen Trading Up 9.5 %

Shares of XGN stock opened at $3.93 on Wednesday. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. The company has a market cap of $70.34 million, a price-to-earnings ratio of -4.18 and a beta of 1.40. Exagen Inc. has a 1 year low of $1.30 and a 1 year high of $6.22. The firm has a fifty day moving average price of $3.89 and a 200-day moving average price of $3.65.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).